

RECEIVED
CENTRAL FAX CENTER
APR 30 2009

Utility Patent
Ser. No. 10/564,861

CLAIM AMENDMENTS

Please amend Claim 1 (~~strikethrough~~ for deletion and underline for insertion):

1. (Currently amended) A method of treatment for lung carcinoma, ~~breast cancer, gastric cancer, and colon cancer, kidney cancer, pancreatic cancer, malignant melanoma, and malignant and low differentiated lymphoma, and certain oncological diseases,~~ said method comprises a step of introducing a treatment agent into a circulating blood system of a cancer patient diagnosed with at least one of the ~~foregoing~~ said cancers and diseases, said treatment agent destroys extracellular DNA in said blood of said cancer patient, wherein said treatment agent used to destroy said extracellular DNA is a DNase enzyme; and wherein said treatment agent is administered in doses and regimens which provide blood plasma DNA-hydrolytic activity, - measured in blood plasma, to exceed 150 Kunitz units per liter of plasma during more than 12 hours in total within 24 hours.
2. (Cancelled)
3. (Cancelled)
4. (Previously Presented) The method according to claim 1, wherein doses of said treatment are introduced to the patient according to a regime schedule which is carried out continuously for no less than 48 hours.

Utility Patent
Scr. No. 10/564,861

5. (Cancelled).
6. (Previously Presented) The method according to claim 1, wherein bovine pancreatic DNase is said agent used to destroy said extracellular DNA, said bovine pancreatic DNase is parenterally introduced in doses ranging from 50,000 Kunitz units to 250,000,000 Kunitz units a day for 5-360 days.
7. (Previously Presented) The method according to claim 1, wherein human recombinant DNase is used.
8. (Previously Presented) The method according to claim 7, wherein human recombinant DNase 1 (Dnase alpha) is parenterally introduced in doses 1,15 mg/kg-500mg/kg of body weight daily during 5-360 days.
9. (Previously Presented) The method according to claim 1, wherein the treatment is carried out from a diagnosis of the cancer and to a remaining term of the patient's life.
10. (Currently Amended) The method according to claim 1, further including a step of introducing a binding agent into said blood system, said binding agent binds said extracellular DNA, wherein said binding agent is anti-DNA antibodies.

Utility Patent
Ser. No. 10/564,861

11. (Cancelled).

12. (Cancelled).

13. (Cancelled).

14. (Cancelled)

15. (Cancelled).